ry, visit www.thaos.net.
This product’s label may have been updated. For full prescribing information, please visit1985. Advise pregnant women and females ofreproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a[see Use in Specificof the availability of the TransthyretinAmyloidosis Outcome Survey (THAOS) registry, that their participation is voluntary, and may involveup. THAOS is an international disease registry designed to assess disease progression,
notype/phenotype relationships, and the impact of interventions, including VYNDAQEL and VYNDAMAXThis product’s label may have been updated. For full prescribing information, please visit www.pfizer.com.
|
